NEW YORK – German molecular diagnostics firm Mainz Biomed said Wednesday that it has entered a partnership with Italian laboratory firm TomaLab to launch Mainz's flagship ColoAlert colorectal cancer screening test in Italy.
The firms said the collaboration will make the PCR-based ColoAlert test available in Italy for at-home stool sample collection for the early detection of colorectal cancer and precancerous lesions. ColoAlert combines DNA and RNA analysis with fecal immunohistochemistry. TomaLab CEO Riccardo Manca said in a statement that his firm will incorporate ColoAlert into the firm's laboratory procedures.
"This partnership underlines our dedication to embracing cutting-edge technologies that enhance patient care and outcomes," he said.
Mainz CEO Guido Baechler added that TomaLab is an ideal partner because of its state-of-the-art facilities and commitment to innovation.
Mainz reported in November that it had received promising interim results from its ColoFuture study on a next-generation colorectal cancer screening assay that would integrate a portfolio of mRNA biomarkers. The current generation ColoAlert test is available through partnerships with regional labs in some countries in Europe and the Middle East.
